No randomized clinical trials have directly compared empagliflozin with dapagliflozin for type 2 diabetes, so investigators conducted a large comparative effectiveness study examining kidney outcomes.

First-line empagliflozin, taken once daily for 3 months, leads to a significant reduction in weight, body mass index (BMI), and waist circumference in patients with prediabetes and diabetes.

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the drug. Adding CKD to the ...

The FDA has granted a speedy review of Eli Lilly and Boehringer Ingelheim’s Jardiance for a potential new use, to reduce the risk of renal failure and cardiovascular death in people with chronic ...

HHS told the Sec­ond Cir­cuit that Boehringer In­gel­heim’s vol­un­tary par­tic­i­pa­tion in Medicare ne­go­ti­a­tions “un­der­mines” its le­gal chal­lenge to the process.